|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Genzyme_Genetics
|
|
gptkbp:approves
|
gptkb:2006
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Sprycel
|
|
gptkbp:category
|
gptkb:D
not recommended
|
|
gptkbp:class
|
tyrosine kinase inhibitor
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:composed_of
|
gptkb:chemical_compound
|
|
gptkbp:contraindication
|
severe liver impairment
hypersensitivity to dasatinib
|
|
gptkbp:developed_by
|
gptkb:Bristol-Myers_Squibb
|
|
gptkbp:discovered_by
|
gptkb:2006
|
|
gptkbp:dosage_form
|
oral tablet
|
|
gptkbp:excretion
|
biliary
|
|
gptkbp:formulation
|
gptkb:tablet
|
|
gptkbp:frequency
|
once daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dasatinib
|
|
gptkbp:indication
|
gptkb:Philadelphia_chromosome-positive_leukemia
|
|
gptkbp:ingredients
|
C22 H26 Cl N5 O2 S
|
|
gptkbp:interacts_with
|
CY P3 A4
CY P2 D6
CY P2 C8
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:is_atype_of
|
L01 X E05
|
|
gptkbp:is_used_for
|
gptkb:chronic_myeloid_leukemia
gptkb:healthcare_organization
|
|
gptkbp:lifespan
|
3 to 5 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
gptkb:Sprycel
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
headache
nausea
diarrhea
rash
skin reactions
pulmonary hypertension
thrombocytopenia
cardiac arrhythmias
hepatotoxicity
hyperglycemia
neutropenia
pleural effusion
hypophosphatemia
hypocalcemia
|
|
gptkbp:social_structure
|
heterocyclic compound
|
|
gptkbp:targets
|
gptkb:BCR-ABL_tyrosine_kinase
|
|
gptkbp:weight
|
488.99 g/mol
|